PolyPid (PYPD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $132.25M
Last updated: Nov 17, 2026 at 11:05 AM ET
PolyPid (PYPD) Earnings: Report Dates and Results
PolyPid (PYPD) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, PolyPid reported EPS of -$0.24, below the $0.46 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PYPD has an expected report date of Feb 9, 2027.
PYPD Earnings Call
The latest PYPD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 27 quarters below that had an estimate, PYPD beat 18 and missed 9. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 152.17% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.24 | $0.46 | N/A | -152.17% | Miss | N/A | 3 | 1 up, 0 down | Nov 11, 2026 |
| Jun 30, 2026 | -$0.35 | -$0.34 | -$0.49 - -$0.32 | -2.94% | Miss | N/A | 4 | 1 up, 1 down | Aug 12, 2026 |
| Mar 31, 2026 | -$0.35 | -$0.43 | -$0.49 - -$0.37 | +18.60% | Beat | N/A | 3 | 0 up, 1 down | May 13, 2026 |
| Dec 31, 2025 | -$0.41 | -$0.33 | -$0.38 - -$0.30 | -24.24% | Miss | N/A | 4 | 3 up, 1 down | Feb 11, 2026 |
| Sep 30, 2025 | -$0.37 | -$0.52 | -$0.69 - -$0.39 | +28.85% | Beat | N/A | 4 | 0 up, 2 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.78 | -$0.55 | -$0.70 - -$0.41 | -41.82% | Miss | N/A | 4 | N/A | Aug 13, 2025 |
| Mar 31, 2025 | -$0.70 | -$0.82 | -$0.84 - -$0.80 | +14.63% | Beat | N/A | 2 | 0 up, 0 down | May 14, 2025 |
| Dec 31, 2024 | -$1.07 | -$0.88 | -$1.04 - -$0.71 | -21.59% | Miss | N/A | 4 | N/A | Feb 12, 2025 |
| Sep 30, 2024 | -$1.22 | -$1.00 | -$1.12 - -$0.88 | -22.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 13, 2024 |
| Jun 30, 2024 | -$1.25 | -$1.30 | -$1.51 - -$1.19 | +3.85% | Beat | N/A | 3 | 0 up, 0 down | Aug 14, 2024 |
| Mar 31, 2024 | -$1.37 | -$1.41 | -$1.96 - -$1.08 | +2.84% | Beat | N/A | 3 | 1 up, 0 down | May 8, 2024 |
| Dec 31, 2023 | -$3.84 | -$4.29 | -$5.16 - -$2.17 | +10.49% | Beat | N/A | 3 | 0 up, 0 down | Feb 14, 2024 |
| Sep 30, 2023 | -$3.40 | -$4.43 | -$5.04 - -$3.62 | +23.25% | Beat | N/A | 3 | 1 up, 0 down | Nov 8, 2023 |
| Jun 30, 2023 | -$10.80 | -$13.32 | N/A | +18.92% | Beat | N/A | 2 | 0 up, 0 down | Aug 9, 2023 |
| Mar 31, 2023 | -$8.40 | -$4.80 | -$12.31 - -$4.80 | -75.00% | Miss | N/A | 3 | 1 up, 0 down | May 10, 2023 |
| Dec 31, 2022 | -$9.60 | -$12.36 | -$14.41 - -$10.51 | +22.33% | Beat | N/A | 4 | 0 up, 0 down | Feb 8, 2023 |
| Sep 30, 2022 | -$14.40 | -$16.22 | -$17.72 - -$14.71 | +11.22% | Beat | N/A | 4 | 1 up, 0 down | Nov 9, 2022 |
| Jun 30, 2022 | -$18.30 | -$20.10 | N/A | +8.96% | Beat | N/A | N/A | 0 up, 0 down | Aug 10, 2022 |
| Mar 31, 2022 | -$18.90 | -$18.92 | -$20.72 - -$17.72 | +0.11% | Beat | N/A | 6 | 0 up, 0 down | May 11, 2022 |
| Dec 31, 2021 | -$21.30 | -$16.64 | -$19.22 - -$15.32 | -28.00% | Miss | N/A | 6 | N/A | Feb 9, 2022 |
| Sep 30, 2021 | -$15.90 | -$18.83 | -$19.82 - -$17.42 | +15.56% | Beat | N/A | 5 | N/A | Nov 10, 2021 |
| Jun 30, 2021 | -$16.80 | -$15.75 | -$18.02 - -$13.51 | -6.67% | Miss | N/A | 5 | N/A | Aug 11, 2021 |
| Mar 31, 2021 | -$14.10 | -$15.00 | -$16.82 - -$13.51 | +6.00% | Beat | N/A | 4 | N/A | May 12, 2021 |
| Dec 31, 2020 | -$12.30 | -$15.23 | -$21.92 - -$11.71 | +19.24% | Beat | N/A | 4 | N/A | Feb 10, 2021 |
| Sep 30, 2020 | -$10.50 | -$12.20 | -$14.41 - -$9.91 | +13.93% | Beat | N/A | 4 | N/A | Nov 11, 2020 |
| Jun 30, 2020 | -$191.10 | -$207.21 | N/A | +7.77% | Beat | N/A | 4 | N/A | Aug 19, 2020 |
| Mar 31, 2020 | -$0.33 | -$12.60 | N/A | +97.42% | Beat | N/A | N/A | N/A | Jun 29, 2020 |
| Dec 31, 2017 | -$3.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 14, 2018 |
| Sep 30, 2017 | -$0.86 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 20, 2017 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.26, after -$4.91 the year before. It was -$4.09 for the year ended Dec 31, 2017, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.26 | N/A |
| Dec 31, 2024 | -$4.91 | N/A |
| Dec 31, 2023 | -$26.44 | N/A |
| Dec 31, 2022 | -$61.20 | N/A |
| Dec 31, 2021 | -$68.10 | N/A |
| Dec 31, 2020 | -$214.23 | N/A |
| Dec 31, 2017 | -$4.09 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,400 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,393 | 10 | |
| 2026Q2 | Jun 30, 2026 | 4,836 | 9 | |
| 2026Q1 | Mar 31, 2026 | 3,874 | 9 | |
| 2025Q4 | Dec 31, 2025 | 4,408 | 9 | |
| 2025Q3 | Sep 30, 2025 | 3,823 | 8 | |
| 2025Q2 | Jun 30, 2025 | 2,998 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,746 | 7 | |
| 2024Q4 | Dec 31, 2024 | 4,047 | 9 |
2026Q3 Earnings Call
Opening remarks
Yehuda Leibler Investor Relations Thank you, operator. Thank you all for joining PolyPid's third quarter 2026 earnings conference call. Earlier today, PolyPid released its financial results for the three and nine months ended September 30, 2026. A copy of the press release is available in the investor section of the company's website at www.polypid.com. Joining me on the call today are Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Ori Warshavsky, Chief Operating Officer, U.S., of PolyPid; and Jonny Missulawin, Chief Financial Officer of PolyPid. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. These include statements about the FDA's review of the D-PLEX100 NDA, including labeling discussions, the PDUFA goal date, and the FDA pre-approval inspection. They also cover the potential approval of D-PLEX100 and the anticipated timing of its U.S. commercial launch by Azurity Pharmaceuticals, as well as potential reimbursement for D-PLEX100, including the anticipated timing of a CMS decision on a New Technology Add-on Payment, or NTAP. We will also discuss the potential label expansion of D-PLEX100 and planned communications with the FDA, and the EMA's review of the MAA for D-PLEX100, including the anticipated timing of the decision and a potential U.S. launch. In addition, we will refer to the company's plans for Europe, Canada, and other territories, including potential partnerships and their timing. Finally, these statements include the company's PolyPid 2030 vision and levers for growth, the development plans and anticipated timing for PD01B and PD03A, and the company's expectation that its cash resources will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in the company's filings with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC, including its annual report on Form 20-F, filed on February 25, 2026. PolyPid disclaims any intention or obligation, except as required by law, to update or revise any forward-looking statements. This conference call contains time-sensitive information that speaks only as of the live broadcast today, November 11, 2026. With that, it's my pleasure to turn the call over to Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. Dikla?
Dikla Akselbrad CEO Thank you, Yehuda, and good morning, everyone. We are now just over two weeks from our PDUFA goal date of November 28, and this is a defining moment for PolyPid. Let me start with the FDA review.
Frequently Asked Questions About PYPD
When is PolyPid's next earnings date?
PolyPid's next earnings report is expected for Feb 9, 2027.
Did PYPD beat earnings estimates last quarter?
No. PolyPid reported EPS of -$0.24 for the quarter ended Sep 30, 2026, below the $0.46 estimate by 152.17%.
What EPS do analysts expect from PYPD next quarter?
The consensus EPS estimate for PolyPid for the quarter ending Dec 31, 2026 is -$0.41 from 7 analysts, with estimates from -$0.55 to -$0.30.
How often does PYPD beat earnings estimates?
PolyPid beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -22.59%.
PYPD pages: Overview, Earnings, Forecast, Competitors